These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 11368819)

  • 1. Jail inmates and HIV care: provision of antiretroviral therapy and Pneumocystis carinii pneumonia prophylaxis.
    White MC; Mehrotra A; Menendez E; Estes M; Goldenson J; Tulsky JP
    Int J STD AIDS; 2001 Jun; 12(6):380-5. PubMed ID: 11368819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count <200 cells/microL?
    ; Mocroft A; Reiss P; Kirk O; Mussini C; Girardi E; Morlat P; Stephan C; De Wit S; Doerholt K; Ghosn J; Bucher HC; Lundgren JD; Chene G; Miro JM; Furrer H
    Clin Infect Dis; 2010 Sep; 51(5):611-9. PubMed ID: 20645862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of antiretroviral therapy in a cohort of HIV infected patients going in and out of the San Francisco county jail.
    Pai NP; Estes M; Moodie EE; Reingold AL; Tulsky JP
    PLoS One; 2009 Sep; 4(9):e7115. PubMed ID: 19771176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pneumocystis jiroveci pneumonia prophylaxis is not required with a CD4+ T-cell count < 200 cells/microl when viral replication is suppressed.
    D'Egidio GE; Kravcik S; Cooper CL; Cameron DW; Fergusson DA; Angel JB
    AIDS; 2007 Aug; 21(13):1711-5. PubMed ID: 17690568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discontinuation of prophylaxis for Pneumocystis carinii pneumonia in HIV-1-infected patients treated with highly active antiretroviral therapy.
    Schneider MM; Borleffs JC; Stolk RP; Jaspers CA; Hoepelman AI
    Lancet; 1999 Jan; 353(9148):201-3. PubMed ID: 9923876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. Swiss HIV Cohort Study.
    Furrer H; Egger M; Opravil M; Bernasconi E; Hirschel B; Battegay M; Telenti A; Vernazza PL; Rickenbach M; Flepp M; Malinverni R
    N Engl J Med; 1999 Apr; 340(17):1301-6. PubMed ID: 10219064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection. Grupo de Estudio del SIDA 04/98.
    Lopez Bernaldo de Quiros JC; Miro JM; Peña JM; Podzamczer D; Alberdi JC; Martínez E; Cosin J; Claramonte X; Gonzalez J; Domingo P; Casado JL; Ribera E;
    N Engl J Med; 2001 Jan; 344(3):159-67. PubMed ID: 11172138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. EuroSIDA Study Group.
    Weverling GJ; Mocroft A; Ledergerber B; Kirk O; Gonzáles-Lahoz J; d'Arminio Monforte A; Proenca R; Phillips AN; Lundgren JD; Reiss P
    Lancet; 1999 Apr; 353(9161):1293-8. PubMed ID: 10218526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy. Eight European Study Groups.
    Ledergerber B; Mocroft A; Reiss P; Furrer H; Kirk O; Bickel M; Uberti-Foppa C; Pradier C; D'Arminio Monforte A; Schneider MM; Lundgren JD;
    N Engl J Med; 2001 Jan; 344(3):168-74. PubMed ID: 11188837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discontinuation of Pneumocystis jirovecii pneumonia prophylaxis with CD4 count <200 cells/µL and virologic suppression: a systematic review.
    Costiniuk CT; Fergusson DA; Doucette S; Angel JB
    PLoS One; 2011; 6(12):e28570. PubMed ID: 22194853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pneumocystis carinii pneumonia in HIV-infected patients.
    May TA; Gruta CI; Goldschmidt RH
    Am Fam Physician; 2000 Oct; 62(8):1783, 1786. PubMed ID: 11057837
    [No Abstract]   [Full Text] [Related]  

  • 12. Discontinuation of primary prophylaxis in HIV-infected patients at high risk of Pneumocystis carinii pneumonia: prospective multicentre study.
    Furrer H; Opravil M; Rossi M; Bernasconi E; Telenti A; Bucher H; Schiffer V; Boggian K; Rickenbach M; Flepp M; Egger M;
    AIDS; 2001 Mar; 15(4):501-7. PubMed ID: 11242147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. No need for secondary Pneumocystis jirovecii pneumonia prophylaxis in adult people living with HIV from Europe on ART with suppressed viraemia and a CD4 cell count greater than 100 cells/µL.
    Atkinson A; Miro JM; Mocroft A; Reiss P; Kirk O; Morlat P; Ghosn J; Stephan C; Mussini C; Antoniadou A; Doerholt K; Girardi E; De Wit S; Kraus D; Zwahlen M; Furrer H;
    J Int AIDS Soc; 2021 Jun; 24(6):e25726. PubMed ID: 34118121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiretroviral outcomes in South African prisoners: a retrospective cohort analysis.
    Davies NE; Karstaedt AS
    PLoS One; 2012; 7(3):e33309. PubMed ID: 22470448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prophylaxis against Pneumocystis carinii pneumonia among children with perinatally acquired human immunodeficiency virus infection in the United States. Pneumocystis carinii Pneumonia Prophylaxis Evaluation Working Group.
    Simonds RJ; Lindegren ML; Thomas P; Hanson D; Caldwell B; Scott G; Rogers M
    N Engl J Med; 1995 Mar; 332(12):786-90. PubMed ID: 7862183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of Pneumocystis carinii pneumonia in HIV-infected persons. Pulmonary Complications of HIV Infection Study Group.
    Stansell JD; Osmond DH; Charlebois E; LaVange L; Wallace JM; Alexander BV; Glassroth J; Kvale PA; Rosen MJ; Reichman LB; Turner JR; Hopewell PC
    Am J Respir Crit Care Med; 1997 Jan; 155(1):60-6. PubMed ID: 9001290
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discontinuation of primary prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus type I-infected patients: the changes in opportunistic prophylaxis study.
    Mussini C; Pezzotti P; Govoni A; Borghi V; Antinori A; d'Arminio Monforte A; De Luca A; Mongiardo N; Cerri MC; Chiodo F; Concia E; Bonazzi L; Moroni M; Ortona L; Esposito R; Cossarizza A; De Rienzo B
    J Infect Dis; 2000 May; 181(5):1635-42. PubMed ID: 10823763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive factors for immunological and virological endpoints in Thai patients receiving combination antiretroviral treatment.
    Srasuebkul P; Ungsedhapand C; Ruxrungtham K; Boyd MA; Phanuphak P; Cooper DA; Law MG
    HIV Med; 2007 Jan; 8(1):46-54. PubMed ID: 17305932
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Geographic distribution of human immunodeficiency virus-associated Pneumocystis carinii pneumonia in San Francisco.
    Morris AM; Swanson M; Ha H; Huang L
    Am J Respir Crit Care Med; 2000 Nov; 162(5):1622-6. PubMed ID: 11069786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of Routine HIV Opt-Out Screening and Continuum of Care Services Following Entry into Eight Prison Reception Centers--California, 2012.
    Lucas KD; Eckert V; Behrends CN; Wheeler C; MacGowan RJ; Mohle-Boetani JC
    MMWR Morb Mortal Wkly Rep; 2016 Feb; 65(7):178-81. PubMed ID: 26914322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.